NBRVF — Nabriva Therapeutics Share Price
0.000.00%
Last trade - 00:00- $0.00m
- -$1.64m
- $36.94m
- 15
- 56
- 57
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -602.21% | ||
| Operating Margin | -182.81% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 9.66 | 9.48 | 5.03 | 28.89 | 36.94 | 70.77 | 103.83 | 47.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nabriva Therapeutics PLC is a biopharmaceutical company. The Company is engaged in the commercialization, research and development of novel anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum β-lactamase-, or ESBL-producing Enterobacteriaceae.
Directors
- Daniel Burgess NEC (59)
- Steven Gelone PRE (52)
- Theodore Schroeder CEO (66)
- Daniel Dolan CFO (44)
- Robert Crotty GCN (47)
- Christine Guico-pabia OTH
- Colin Broom DRC (65)
- Carrie Bourdow IND (58)
- Mark Corrigan IND (63)
- Lisa Dalton IND (48)
- Charles Rowland IND (62)
- Stephen Webster IND (60)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- March 1st, 2017
- Public Since
- September 18th, 2015
- No. of Shareholders
- 24
- No. of Employees
- 39
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 3,230,837
- Address
- Alexandra House Office 225/227, DUBLIN, D01 H104
- Web
- https://www.nabriva.com/
- Phone
- +353 6108166640
- Auditors
- KPMG LLP
Upcoming Events for NBRVF
Similar to NBRVF
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Nabriva Therapeutics share price?
As of Today at 22:13 UTC, shares in Nabriva Therapeutics are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Nabriva Therapeutics share price performed this year?
Shares in Nabriva Therapeutics last closed at $0.00 and the price had moved by -100% over the past 365 days. In terms of relative price strength the Nabriva Therapeutics share price has underperformed the S&P500 Index by -100% over the past year.
What are the analyst and broker recommendations for Nabriva Therapeutics?
The overall consensus recommendation for Nabriva Therapeutics is Sell. You can view the full broker recommendation list by unlocking its StockReport.
What is the Nabriva Therapeutics dividend yield?
Nabriva Therapeutics does not currently pay a dividend.
Does Nabriva Therapeutics pay a dividend?
Nabriva Therapeutics does not currently pay a dividend.
When does Nabriva Therapeutics next pay dividends?
Nabriva Therapeutics does not currently pay a dividend.
How do I buy Nabriva Therapeutics shares?
To buy shares in Nabriva Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nabriva Therapeutics?
As of the previous close price of $0.00, shares in Nabriva Therapeutics had a market capitalisation of $0.00m.
Where are Nabriva Therapeutics shares listed?
Here are the trading details for Nabriva Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NBRVF
What kind of share is Nabriva Therapeutics?
Based on an overall assessment of its quality, value and momentum Nabriva Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nabriva Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Nabriva Therapeutics is $1.00. That is 99999900% above the last closing price of $0.00.
Analysts covering Nabriva Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$8.76 for the next financial year.
What is the trend in the Nabriva Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nabriva Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -9.44%.
As of the last closing price of $0.00, shares in Nabriva Therapeutics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nabriva Therapeutics PE Ratio?
The Nabriva Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nabriva Therapeutics?
Nabriva Therapeutics' management team is headed by:
- Daniel Burgess - NEC
- Steven Gelone - PRE
- Theodore Schroeder - CEO
- Daniel Dolan - CFO
- Robert Crotty - GCN
- Christine Guico-pabia - OTH
- Colin Broom - DRC
- Carrie Bourdow - IND
- Mark Corrigan - IND
- Lisa Dalton - IND
- Charles Rowland - IND
- Stephen Webster - IND